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INTRODUCTION
Kawasaki disease (KD) is a multi-systemic type of vasculi-
tis including coronary involvement (1). It is an acute, febrile,
and exanthematous illness that primarily affects infants and
young children characterized by wide spread vascular inflam-
mation of coronary arteries and other medium sized arteries
(2). Coronary artery lesions (CAL), coronary artery dilatation or
aneurysms, are the most important complications and devel-
op in approximately 15-25% of affected patients with KD
(3). Immunological abnormalities during the acute phase of
KD are characterized by the activation of immunoregulatory
cells and an excess production of inflammatory mediators (4).
The activated neutrophils and monocytes, producing a large
amount of matrix metalloproteinases (MMPs), migrate into
vascular lesions, and newly produced MMPs are thought to
be related with coronary artery complications in KD (5).
Polymorphisms of MMP-3 and MMP-9 genes have been
reported to be associated with disease susceptibility, severity
and progression of atherosclerosis and aneurysms (6-9). The
polymorphism in the promoter region of MMP-3 gene on
chromosome 11q 22 has been identified (6) and it is bi-allelic
with one variant containing a run of 6 adenosines (6A) while
the other has five (5A). This MMP-3 5A allele has higher
transcriptional activity than 6A allele (10). Two types of poly-
morphisms in the MMP-9 gene on chromosome 20q 12.2-
13.1 have been shown to be functionally important (7). These
are a (CA)n microsatellites polymorphism at position -90 (11)
and a single nucleotide polymorphism at position -1562 of
the translation start site. The cytosine to thymidine transi-
tion at position -1562 of the MMP-9 gene is associated with
approximately 50% greater promoter activity than that of
C-allele (9). 
These findings led to us to hypothesize that these polymor-
phisms, which modify the transcriptional activities of MMPs,
could be genetic risk factors for CAL in KD.
MATERIALS AND METHODS
Study population 
One hundred controls with no history of Kawasaki disease
(KD), autoimmune disease, or allergic diseases (50 males and
50 females, range 1 to 77 yr olds) were recruited for geno-
typing of MMP-3 and MMP-9 promoter gene polymorphism.
Adult healthy controls were enrolled from subjects attend-
ing routine medical check-ups and child controls were admit-
ted for elective surgery or transient acute infection. We ret-
rospectively reviewed the medical records of 121 KD patients
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Polymorphism of Matrix Metalloproteinase-3 Promoter Gene as a Risk
Factor for Coronary Artery Lesions in Kawasaki Disease
Kawasaki disease (KD) is a major cause of acquired coronary artery diseases in
childhood. The serum levels of matrix metalloproteinase (MMP)-3 and MMP-9 in
KD have been reported to be significantly higher than other diseases. Several
studies have demonstrated that MMP-3 5A/6A polymorphism and MMP-9 C-1562T
polymorphism modify each transcriptional activity in allele specific manner. We
hypothesized that these polymorphisms may play a role as a risk factor for devel-
opment of coronary artery lesions (CAL) in KD. Eighty-three patients, diagnosed
with KD in Cheju National University Hospital from January 2000 to February
2004, were divided into two groups according to the presence of CAL. Genotyping
of MMP-3 and MMP-9 gene polymorphisms were determined by restriction frag-
ment length polymorphism. With regard to MMP-3 gene polymorphism, the KD
with CAL group had a higher frequency of 6A/6A genotype than control group (p=
0.0127) and the KD without CAL group (p=0.0036). However, no significant differ-
ences in the allele and genotype distributions of the MMP-9 polymorphism were
observed. These findings suggest that MMP-3 6A/6A genotype may be an inde-
pendent risk factor for CAL formation in KD.
Key Words : Matrix Metalloproteinases; Kawasaki Disease; Mucocutaneous Lymph Node Syndrome; Coro-
nary Vessels; Polymorphism, Genetic
Received : 3 February 2005
Accepted : 4 April 2005608 J.-A. Park, K.-S. Shin, Y.W. Kim
at the Cheju National University Hospital, Jeju, Korea, from
January 2000 to February 2004. KD was diagnosed accord-
ing to the criteria proposed by the Japanese Kawasaki Disease
Research Committee (12). Echocardiography was obtained
within 2 weeks of the onset or before intravenous immuno-
globulin administration. Forty-two patients (34.7%) had
CALs on echocardiography. The CAL was defined as the cri-
teria proposed by Nakano et al. (13); the largest diameter of
coronary artery was greater than 2.5 mm in children with a
body surface area (BSA) of less than 0.5 m2, greater than 3
mm in those of BSA between 0.5 and 1 m2 and more than 4
mm in those of BSA more than 1 m2. Among patients diag-
nosed KD, 83 patients, available for genotyping of MMP
gene polymorphism, were enrolled. Of the 83 patients, 34
patients had coronary artery lesion. Patients were divided
into two groups according to the presence of CAL: 34 patients
with CAL and 49 patients without CAL.
The following laboratory data were analyzed for elucidat-
ing of its association with the development of CAL: white
blood cell (WBC) counts, platelet counts, erythrocyte sedi-
mentation rate (ESR), alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), and C-reactive protein (CRP).
Data from the patient’s first visit to the hospital were obtained.
All controls and parents, whose children were involved in
this study, gave written consent to participation and geno-
typing. This study was approved by the Clinical Research
Committee in Cheju National University Hospital.
Genotype analysis
Genomic DNA was extracted from the peripheral blood
using a genomic DNA purification kit (Wizard�; Promega,
Madison, WI, U.S.A.) according to the provided protocol.
Genotyping of MMP-3 and MMP-9 promoter gene polymor-
phism were determined by restriction fragment length poly-
morphism, as previously described (14, 15).
5A/6A polymorphism in the promoter region of MMP-3 
Genotyping of MMP-3 promoter polymorphism was exam-
ined with a modification of the method described by Dun-
leavey et al. (14). In brief, PCR amplification was conducted
with the primer (5′ -GAT TACAGA CAT GGG TCA CA-
3′and 5′ -TTT CAA TCA GGA CAA GAC GAA GTT T-
3′ ), annealed to the proximity of the 5A/6A polymorphism.
Genomic DNA was amplified in 50  L of reaction mixture
containing 10 pM of each primer, 0.2 mM dNTPs, 2 mM
MgCl2, and 2.0 U Taq polymerase (Promega, Madison, WI).
The amplification conditions were as follow: 94℃ for 30 sec,
55℃ for 30 sec, and 72℃ for 30 sec, for a total 35 cycles
with an extension at 72℃ for 7 min. The resulting 120 bp
PCR product was digested XmnI restriction endonuclease
(Promega). The 5A allele, possessing a recognition sequence
5′ -GAA (N)4 TTC-3′for XmnI, cleaved the PCR product
to 97 bp and 23 bp fragments. The PCR product deriving
from the 6A allele, contains 5′ -GAA (N)5 TTC-3′did not
digested by XmnI. Undigested PCR product was sequenced
(ABI Prism 377 automatic sequencer) to confirm the 6A allele.
C-1562T promoter polymorphism of MMP-9
Genomic DNA were PCR-amplified in a 50  L reaction
mixture containing 10 pM of each primers (5′ -GCC TGG
CAC ATA GTA GGC CC-3′and 5′ -CTT CCT AGC CAG
CCG GCA TC-3′ ), 0.2 mM dNTPs, 100 mM Tris-HCl, pH
8.3, 1.5 mM MgCl2, and 2.0 U Taq polymerase (Promega).
The amplification conditions were as follow: 95℃ for 1 min,
63℃for 1 min, and 72℃for 1 min, for a total 35 cycles with
an extension at 72℃ for 5 min. PCR products were digest-
ed with 2U of SphI restriction endonuclease (Promega) over
1 hr at 37℃. The final products were electrophoresed on 2%
agarose gel and visualized directly with ethidium-bromide
staining. The T allele at SphI site gives rise to a 435 bp frag-
ment rather than one of 247 bp or 188 bp fragments for C
allele.
Statistical analysis
The SPSS package (SPSS 10.0 for Windows) was used for
statistical analysis. Allele frequencies were deduced from
genotype frequencies, and differences in the distribution of
genotypes were determined by the chi-square test. In order to
analyze the comparison of the frequencies of combined geno-
type between the KD with CAL group and the KD without
CAL group, the chi-square test from 2×4 contingency table
was applied. Clinical parameters between the KD with CAL
group and the KD without CAL group were expressed as
mean±standard deviation and were compared by using the
Student’s t-test. P less than 0.05 were accepted as statistical-
ly significant.
RESULTS
The distributions of the MMP-3 and MMP-9 genotype are
shown in Table 1. The observed distributions of the MMP-3
and MMP-9 genotype were in Hardy-Weinberg equilibrium.
No significant differences in the distribution of MMP-3 and
MMP-9 genotype and allelic frequency were observed between
control and patient groups (Table 1). There was no significant
difference between the KD with CAL group and KD with-
out CAL group with respect to sex, age at diagnosis, dura-
tion of fever, WBC and platelet count, ESR, serum levels of
aspartate aminotransferase (AST), and C-reactive protein (CRP)
(Table 2). The KD with CAL group demonstrated signifi-
cantly higher serum levels of alanine aminotransferase (ALT)
in acute phase than the KD without CAL group (56.07±
66.93 IU/L versus 98.43±113.41 IU/L, p<0.05, Table 2). Matrix Metalloproteinase-3 Promoter Gene Polymorphism in Kawasaki Disease 609
We assessed the association of MMP-3 and 9 gene poly-
morphisms with development of CAL in KD patients. For
MMP-9 C-1562T polymorphism, no significant association
was observed between control group and the KD with CAL
group or the KD without CAL group and the KD with CAL
group (Table 3). T allele carriers were more frequently observed
in patients without CAL compared with patients with CAD
or control group, but these differences were not statistically
significant. For MMP-3 gene polymorphism, the KD with
CAL group had a higher frequency of 6A/6A genotype than
control group (p=0.0127, OR=0.18 (0.03 to 0.84)) and the
KD without CAL group p=0.0036, OR=0.13 (0.02 to 0.66),
Table 3). For the combination of MMP-3 and MMP-9 gene
polymorphism, 4 major combined genotypes in the study
groups were 6A/6A C/C, 6A/6A C/T, 6A/5A C/C, and 6A/5A
C/T. Combined 6A/5A C/T genotype was not observed in the
KD with CAL group (Table 3). The frequency of the 6A/6A
C/C genotype was greater in the KD with CAL group than
in the KD without CAL group, and the KD with CAL group
had less often the 6A/5A C/C genotype than the KD with-
out CAL group (p=0.0169, Table 3).
DISCUSSION
In KD, CAL appeared within the first 4 weeks of illness,
and more than half of CALs were gradually regressed within
1 yr after onset. However, some might be progressed into
completely obstructive or markedly stenotic coronary lesions
(3). Fujiwara et al. (16) documented four stages in the patholo-
gy of the coronary arteries under KD. Acute inflammatory
changes are seen in the first 6-9 days in the intima and adven-
titia, and become panvascular lesions by 12-25 days. Subse-
quently, aneurysms are seen mostly within the first 2 weeks
of the early phase of the disease. During the acute stage, large
thrombi are frequently noted, and then marked fibrosis, inti-
mal thickening with recanalization, thrombi, and severe steno-
sis are seen after 40 days. 
MMP-3, an important member of metalloproteinase fam-
ily, is produced by various types of cells; fibroblasts, smooth
muscle cells, and macrophages. MMP-3 potentially contributes
to the development of structural alterations in the vessel wall
by degradation of extracellular matrix proteins such as pro-
teoglycans, laminin, fibronectin and collagen type III, IV, V
and IX (10). MMP-9 is also thought to play an important role
in facilitating the extravasation and migration of neutrophils
by breaking down the basement membrane (17). Senzaki et
al. (5) reported that MMP-9 level in pre-intravenous immuno-
globulin (IVIG) therapy and MMP3 level in the post-IVIG
therapy were significantly higher in KD patients with CAL
than in control group or KD patients without CAL. They
also reported that the mean levels of serum MMPs (MMP-
2, 3, and 9) were significantly higher in KD patients before
IVIG therapy than afebrile control subjects or other febrile
*OR=0.76 (95% CI, 0.39 to 1.47), 
� OR=0.388 (95% CI, 0.74 to 2.49).
MMP, matrix metalloproteinase; OR, odd ratio; CI, confidence interval.
Control (%) Patient (%) p
MMP-3 Genotype 6A/6A 74 (74.0) 65 (78.3) 0.634
6A/5A 23 (23.0) 17 (20.5)
5A/5A 3 (3.0) 1 (1.20)
Total 100 83
Allele 6A 171 (85.5) 147 (88.6) 0.388*
5A 29 (14.5) 19 (11.4)
MMP-9 Genotype C/C 75 (75.0) 56 (67.5) 0.529
C/T 23 (23.0) 25 (30.12)
T/T 2 (2.0) 2 (2.4)
Total 100 83
Allele C 173 (86.5) 137 (82.5) 0.294
�
T 27 (13.5) 29 (17.5)
Table 1. Distribution of genotypes and alleles of MMP-3 and
MMP-9 promoter gene polymorphism
*OR=2.71 (95% CI, 0.85 to 8.95). KD, Kawasaki disease; CAL, coro-
nary artery lesion; WBC, white blood cell; ESR, erythrocyte sedimenta-
tion rate; ALT, alanine aminotransferase; AST, aspartate aminotrans-
ferase; CRP, C-reactive protein.




No. of patients 83 49 34
Sex (male/female) 83 31/18 28/6 0.059*
Age at diagnosis (yr) 83 2.43±1.54 2.28±1.64 0.685
Duration of fever (days) 83 8.25±3.43 8.27±3.47 0.980
WBC (10
3/ L) 83 10.96±3.42 11.06±3.66 0.895
Platelet (10
3/ L) 83 524.30±161.95 604.62±316.70 0.158
ESR (mm/hr) 81 81.33±33.65 104.76±95.74 0.148
ALT (IU/L) 81 56.07±66.93 98.43±113.41 0.049
AST (IU/L) 81 43.21±30.58 47.47±34.20 0.579
CRP (mg/dL) 81 9.79±6.68 14.69±18.23 0.123
Table 2. Relation between clinical parameters in KD patients
and development of CAL
*p=0.0127, OR=0.18 (95% CI, 0.03 to 0.84) vs. control. 
� p=0.0036, OR=
0.13 (95% CI, 0.02 to 0.66) vs. KD without CAL. 
� p=0.0169, vs. KD with-









6A/6A 74 (74.0%) 33 (67.3%) 32 (94.1%)*
�
6A/5A and 5A/5A 26 (26.0%) 16 (32.7%) 2 (5.0%)
MMP-9
C/C 75 (75.0%) 31 (63.3%) 25 (73.5%)
C/T and T/T 25 (25.0%) 18 (36.7%) 9 (26.5%)
Combined Genotype
6A/6A, C/C 55 (55.0%) 22 (44.9%) 24 (70.6%)
�
6A/6A, C/T 17 (17.0%) 11 (22.4%) 7 (20.6%)
6A/5A, C/C 18 (18.0%) 8 (16.3%) 1 (2.9%)
6A/5A, C/T 5 (5.0%) 7 (14.3%) 0 (0.0%)
Table 3. Association of MMP-3 and MMP-9 polymorphism with
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disease subjects (18). Cho et al. (19) reported in the study
with Korean patients that MMP9 levels were significantly
higher before IVIG therapy, and decreased through the con-
valescent stage. The serum MMP9 levels showed significant-
ly positive correlation with the circulating leukocyte counts.
Therefore, we hypothesized that genetic association of MMP
activity may play a role as a susceptibility factor for develop-
ment of CAL in patients with KD.
The MMP-3 5A/6A polymorphism had been analyzed in
the association with atherosclerosis and aortic aneurysms. 5A
allele, higher promoter activity than 6A allele, was more fre-
quent in patients with abdominal aortic aneurysms, intracra-
nial aneurysms (8) and coronary aneurysms (20). Conversely,
6A allele had been found to be associated with angiographic
progression of coronary atherosclerosis (6, 10), restenosis after
balloon angioplasty (21) and accelerated growth of coronary
atheroma (6). In our study, the KD with CAL group had a
higher frequency of 6A/6A genotype than control group or
the KD without CAL group. The 6A/6A genotype is a poten-
tial susceptibility factor for CAL in our study. This result is
paradoxical, given that 6A allele has been associated with lower
transcriptional activity and known to insufficient MMP-3
expression (22). 
The T allele of C-1562 T MMP-9 polymorphism is asso-
ciated with approximately 50% greater promoter activity
than that of C allele. Jones et al. (23) found that genotypes
carrying the T allele of this polymorphism were significant-
ly more common in patients with abdominal aortic aneurysm
compared with controls or patients with peripheral vascular
disease. They concluded that C-1562T MMP-9 promoter
polymorphism is a strong independent risk factor for abdomi-
nal aortic aneurysms. In our study, no significant differences
in the allele and genotype distributions of the MMP-9 poly-
morphism were observed. However, T allele carriers were more
observed in patients without CAL compared with patients
with CAL. 
For the combination of MMP-3 and MMP-9 gene poly-
morphism, the frequency of the 6A/6A C/C genotype was
greater in the KD with CAL group than in the KD without
CAL group, and the KD with CAL group had less often the
6A/5A C/C genotype than the KD without CAL group. The
present results might suggest that development of CAL in
patients with KD is more dependent on genotypes of MMP-3
than that of MMP-9. 
The serum level of ALT is one of the indices of liver damage
and a common test item at the initial examination of patients
with KD. The advantage to examine the data obtained at
the initial examination is that the ALT in KD patient at the
acute stage has not been affected by the salicylate treatment.
Uehara et al. (24) reported that the ALT of 50 IU/L or more
was noted in 49% of the patients with transient cardiac con-
ditions and 52% of those with persistent cardiac disorders.
The elevation of the serum ALT at the initial examination
was related to the complications of both transient and per-
sistent cardiac disorders. In our study, the ALT levels in ini-
tial examination showed significantly higher in the KD with
CAL patients than the KD without CAL patients. However,
the changes in ALT level within an individual could not be
demonstrated because only the data on the ALT measured at
the initial examination were available. Comparing the serum
ALT levels for a large number of patients will clarify more
effectively the role of ALT in patients with KD. 
However, the association of the MMP gene polymorphism
with CAL in KD does not necessarily imply that the genet-
ic variation is responsible for the increased risk of CAL. The
increased levels of MMPs may be related with increased infil-
tration of MMPs producing cells in the coronary artery. More-
over, the association of MMP gene polymorphism with CAL
in KD may arise from racial differences of the study popula-
tions. The frequency of MMP-3 6A allele has been reported
to 65% in Finnish (8), 55% in French (20) and 85% in Korean
(15). In our study, the prevalence of MMP-3 6A allele was
85.5% in controls and 88.6% in KD patients. The preva-
lence of MMP-9 T allele was reported to 22.9% in North
American, 30% in Swedish and 6% in Korean population
(25-27). The frequency of this allele was 13.5% in controls
and 17.5% in KD patients in this study.
In conclusion, polymorphism in the MMP promoter gene
may be contributed to inter-individual differences of the sus-
ceptibility for CAL in KD. This is the first study to evaluate
the association of MMP-3 and MMP-9 gene polymorphism
with CAL in KD. However, to firmly establish the relation-
ship between MMP-3 and MMP-9 gene polymorphism and
CAL in KD, further large-scale studies are required in other
populations.
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